Successful Low-Dose Immune Tolerance Induction Regimen Using Multiple Plasma-Derived Factor VIII Concentrates

被引：0
|
作者：
Colella, M. [1 ]
Montalvao, S. [1 ]
Sambo, A. [1 ]
De Paula, E. [1 ]
Ozelo, M. [1 ]
机构：
[1] Univ Estadual Campinas, Hemophilia Unit Claudio LP Correa INCT Sangue Hem, Campinas, Brazil
来源：
HAEMOPHILIA | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [21] Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors
    Orsini, Frederique
    Rotschild, Chantal
    Beurrier, Philippe
    Faradji, Albert
    Goudemand, Jenny
    Polack, Benoit
    HAEMATOLOGICA, 2005, 90 (09) : 1288 - +
  • [22] ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates
    Peyvandi, Flora
    Mannucci, Pier Mannuccio
    Valsecchi, Carla
    Pontiggia, Silvia
    Bernstein, Jonathan
    Guazzini, Stefano
    Retzios, Anastassios
    BLOOD, 2012, 120 (21)
  • [23] Immunogenicity of low-dose plasma-derived hepatitis B vaccine
    Kane, M
    Milstien, JH
    LANCET, 1997, 350 (9084): : 1102 - 1102
  • [24] Epicutaneous Immunotherapy Using Plasma-Derived Factor VIII Reduces the Inhibitory Immune Response to Therapeutic Factor VIII in Experimental Hemophilia a
    Lacroix-Desmazes, Sebastien
    Porcherie, Adeline
    Delignat, Sandrine
    Ing, Mathieu
    Benhamou, Pierre-Henri
    Mondoulet, Lucie
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB88 - AB88
  • [25] Immune tolerance induction (ITI) in hemophilia A and inhibitors using VWF containing factor VIII concentrates.
    Kreuz, W
    Ettingshausen, CE
    Auerswald, GKH
    Brackmann, HH
    Klingebiel, T
    BLOOD, 2004, 104 (11) : 845A - 845A
  • [26] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [27] TRANSMISSION OF HUMAN PARVOVIRUS B19 BY PLASMA-DERIVED FACTOR-VIII CONCENTRATES
    LAURIAN, Y
    DUSSAIX, E
    PARQUET, A
    CHALVONDEMERSAY, A
    DOIRON, R
    TCHERNIA, G
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1994, 36 (06): : 449 - 453
  • [28] Biological and biochemical assays to ensure the quality and safety of plasma-derived products: Factor VIII concentrates
    Radosevich, Miryana
    Burnouf, Thierry
    CURRENT PHARMACEUTICAL ANALYSIS, 2007, 3 (02) : 83 - 94
  • [29] Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use
    Hajducek, Dagmar M.
    Primacakti, Fitri
    Chozie, Novie
    Mir, Roser
    McEneny-King, Alanna
    Iorio, Alfonso
    Edginto, Andrea
    PLASMATOLOGY, 2021, 15
  • [30] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
12345